Vor Biopharma (VOR) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 06, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Registrant Name	VOR BIOPHARMA INC.
Entity Central Index Key	0001817229
Entity File Number	001-39979
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-1591163
Entity Address, Address Line One	100 Cambridgepark Drive
Entity Address, Address Line Two	Suite 101
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02140
City Area Code	617
Local Phone Number	655-6580
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		37,598,351
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	VOR
Security Exchange Name	NASDAQ

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 90,042	$ 119,801
Marketable securities	91,575	87,668
Prepaid expenses	6,474	4,836
Other current assets	2,212	2,094
Total current assets	190,303	214,399
Restricted cash equivalents	2,413	2,413
Property and equipment, net	11,767	6,853
Operating lease right-of-use assets	21,597	15,670
Other assets	8,189	3,255
Total assets	234,269	242,590
Current liabilities:
Accounts payable	1,255	1,545
Accrued liabilities	9,258	6,335
Operating lease liability	7,281	1,839
Other current liabilities	351	434
Total current liabilities	18,145	10,153
Long-term liabilities:
Operating lease liabilities—non-current	21,677	16,174
Total liabilities	39,822	26,327
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 0 shares issued and outstanding as of March 31, 2022 and December 31, 2021
Common stock, $0.0001 par value; 400,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 37,501,662 and 37,375,428 shares issued and 37,336,314 and 37,174,741 outstanding as of March 31, 2022 and December 31, 2021, respectively	4	4
Additional paid-in capital	348,375	346,382
Accumulated other comprehensive loss	(1,072)
Accumulated deficit	(152,860)	(130,123)
Total stockholders' equity	194,447	216,263
Total liabilities and stockholders' equity	$ 234,269	$ 242,590

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	37,501,662	37,375,428
Common stock, shares outstanding	37,336,314	37,174,741

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 15,280	$ 8,941
General and administrative	7,520	4,789
Total operating expenses	22,800	13,730
Loss from operations	(22,800)	(13,730)
Other income:
Interest income	63	7
Total other income	63	7
Net loss	(22,737)	(13,723)
Cumulative dividends on redeemable convertible preferred stock		(1,228)
Net loss attributable to common stockholders	$ (22,737)	$ (14,951)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.61)	$ (0.67)
Weighted-average common shares outstanding, basic and diluted	37,293,438	22,263,994
Other comprehensive loss:
Unrealized loss on available for sale investments	$ (1,072)
Total other comprehensive loss	(1,072)
Comprehensive loss attributable to common stockholders	$ (23,809)	$ (14,951)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive loss	Accumulated Deficit	Series A-1 Redeemable Convertible Preferred Stock	Series A-2 Redeemable Convertible Preferred Stock	Series B Redeemable Convertible Preferred Stock
Beginning Balance at Dec. 31, 2020	$ (59,065)	$ 1	$ 2,158		$ (61,224)
Beginning Balance, Shares at Dec. 31, 2020		505,074
Beginning Balance at Dec. 31, 2020						$ 2	$ 42,786	$ 64,548
Beginning Balance, Shares at Dec. 31, 2020						20,000,000	107,194,866	124,519,220
Issuance of redeemable convertible preferred stock								$ 45,375
Issuance of redeemable convertible preferred stock, Shares								87,259,605
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering						$ (2)	$ (42,786)	$ (109,923)
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering, Shares						(20,000,000)	(107,194,866)	(211,778,825)
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering	152,711	$ 2	152,709
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering, Shares		24,924,501
Issuance of common stock upon closing of initial public offering, net of offering costs and underwriter fees of $17,132	186,308	$ 1	186,307
Issuance of common stock upon closing of initial public offering, net of offering costs and underwriter fees, Shares		11,302,219
Issuance of common stock upon vesting and exercise of stock options	65		65
Issuance of common stock upon vesting and exercise of stock options, Shares		38,216
Stock-based compensation expense	891		891
Net loss	(13,723)				(13,723)
Ending Balance at Mar. 31, 2021	267,187	$ 4	342,130		(74,947)
Ending Balance, Shares at Mar. 31, 2021		36,770,010
Beginning Balance at Dec. 31, 2021	$ 216,263	$ 4	346,382	$ 0	(130,123)
Beginning Balance, Shares at Dec. 31, 2021	37,174,741	37,174,741
Issuance of common stock upon vesting and exercise of stock options	$ 247		247
Issuance of common stock upon vesting and exercise of stock options, Shares		161,573
Stock-based compensation expense	1,746		1,746
Other comprehensive loss	(1,072)			(1,072)
Net loss	(22,737)				(22,737)
Ending Balance at Mar. 31, 2022	$ 194,447	$ 4	$ 348,375	$ (1,072)	$ (152,860)
Ending Balance, Shares at Mar. 31, 2022	37,336,314	37,336,314

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance of common shares upon closing of initial public offering, offering costs and underwriter fees	$ 17,132

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net loss	$ (22,737)	$ (13,723)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation expense	426	311
Non-cash lease expense	920	322
Stock-based compensation	1,746	891
Other	65
Changes in operating assets and liabilities:
Operating lease liability	(727)	(16)
Prepaid expenses and other current assets	(1,740)	(3,131)
Accounts payable and accrued liabilities	(722)	(2,444)
Other assets	(135)	141
Net cash used in operating activities	(22,904)	(17,649)
Cash flow from investing activities
Purchases of marketable securities	(5,044)
Purchases of property and equipment	(2,011)	(1,171)
Net cash used in investing activities	(7,055)	(1,171)
Cash flow from financing activities
Proceeds from issuance of redeemable convertible preferred stock		45,375
Proceeds from the issuance of common stock upon closing of initial public offering, net of underwriter fees		189,199
Payment of initial public offering costs		(1,744)
Proceeds from stock option exercises	200	18
Net cash provided by financing activities	200	232,848
Net (decrease) increase in cash, cash equivalents and restricted cash equivalents	(29,759)	214,028
Cash, cash equivalents and restricted cash equivalents, beginning of period	122,214	50,098
Cash, cash equivalents and restricted cash equivalents, end of period	92,455	264,126
Supplemental disclosure of non-cash activities
Lease incentive paid by the landlord on behalf of the Company	1,509
Operating right-of-use assets and operating lease liability recorded upon lease commencement	6,266
Purchases of property and equipment in accounts payable and accrued liabilities	$ 3,539	149
Conversion of redeemable convertible preferred stock to common stock upon closing of the initial public offering		152,711
Deferred offering costs in accounts payable and accrued expenses		$ 471

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 90,042	$ 119,801	$ 262,567
Restricted cash equivalents	2,413	2,413	1,559
Total cash, cash equivalents and restricted cash equivalents as shown on the statements of cash flows	$ 92,455	$ 122,214	$ 264,126	$ 50,098

Nature of the Business

Nature of the Business	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Nature of the Business	1. Nature of the Business Vor Biopharma Inc. (the “Company”) is a clinical-stage cell and genome engineering company that combines a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. The Company’s proprietary platform leverages its expertise in hematopoietic stem cell (“HSC”) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company is headquartered in Cambridge, Massachusetts. The Company was incorporated on December 30, 2015 . Risks and Uncertainties The Company is subject to a number of risks common to development stage companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, risks of obtaining regulatory approval for any product candidate that it may develop, development by competitors of technological innovations, compliance with government regulations, the impact of the COVID-19 pandemic, including impacts related to the variants of the virus, and the need to obtain additional financing. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates. The Company believes that its existing cash, cash equivalents and marketable securities at March 31, 2022 will be sufficient to allow the Company to fund its current operations through at least a period of one year after the date the financial statements are issued.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the condensed consolidated financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: estimating the fair value of the Company’s common stock (prior to its initial public offering); accrued expenses and research and development expenses. Unaudited Interim Financial Information The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. The accompanying condensed consolidated balance sheet as of December 31, 2021 has been derived from the Company’s audited consolidated financial statements for the year ended December 31, 2021. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report”). During the three months ended March 31, 2022, other than the adoption of ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , as discussed below, and addition of the cloud computing arrangement accounting policy, there have been no changes to the Company’s significant accounting policies as described in the 2021 Annual Report. Measurement of Credit Losses For financial assets measured at fair value through other comprehensive loss, the Company must record an allowance for credit losses at the end of each reporting period in the condensed consolidated statement of operations. When developing an estimate of expected credit losses on financial assets, the Company will consider available information relevant to assessing the collectability of cash flows. This information may include internal information, external information, or a combination of both, relating to past events, current conditions, and reasonable and supportable forecasts for financial asset pools. The Company’s investment in corporate bonds and U.S. treasury securities, reported as available-for-sale investments, and the associated accrued interest reported as other current assets on the condensed consolidated balance sheets, is the only financial asset pool. The financial asset pool was determined by the type of financial asset instrument and its credit quality. Management does not expect a credit loss with this financial asset pool and determined an allowance was not required based on the issuers' current high quality credit ratings and the lack of default history on its obligations. Cloud Computing Arrangements The Company capitalizes implementation costs for cloud computing arrangement service contracts. The Company’s cloud computing arrangements relate to its enterprise resource planning and manufacturing software. These assets are classified as software and included in property and equipment, net in the consolidated balance sheets and are amortized on a straight-line basis over their assessed useful life beginning when the contract is ready for its intended use. The estimated useful lives of these assets is three years and are subject to the Company’s existing Impairment of Long-Lived Assets accounting policy as described in the 2021 Annual Report. Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13 , Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which has been subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10, ASU 2019-11 and ASU 2020-03 (“ASU 2016-13”). This standard requires that credit losses be recorded using an expected losses model rather than the incurred losses model that was previously used and establishes additional credit risk disclosures associated with financial assets. The adoption of this standard on January 1, 2022, did no t have a significant impact on the Company’s financial statements.

Marketable Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	3. Marketable Securities The amortized cost and estimated fair value of marketable securities, by contractual maturity are as follows: March 31, 2022 (in thousands) Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Maturing in one year or less Corporate bonds $ 7,577 $ — $ ( 26 ) $ 7,551 U.S. Treasuries 55,097 — ( 525 ) 54,572 Maturing after one year through five years Corporate bonds 5,005 — ( 84 ) 4,921 U.S. Treasuries 24,968 — ( 437 ) 24,531 Total $ 92,647 $ — $ ( 1,072 ) $ 91,575 December 31, 2021 (in thousands) Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Maturing in one year or less Corporate bonds $ 7,603 $ — $ — $ 7,603 U.S. Treasuries 30,119 — — 30,119 Maturing after one year through five years Corporate bonds 5,006 — — 5,006 U.S. Treasuries 44,940 — — 44,940 Total $ 87,668 $ — $ — $ 87,668 The unrealized losses of the Company’s marketable securities above were a result of market interest rate increases. The contractual terms of those investments do not permit the issuer to settle the securities at a price less than par value. The Company’s intent is to hold the investments until their maturity and any change in fair value that is not credit related is recognized as an other comprehensive income (loss), net of applicable taxes. A credit-related impairment is recognized as an allowance to the balance sheet with a corresponding adjustment to earnings. The Company did no t recognize any credit losses related to marketable securities for the three months ended March 31, 2022.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis: March 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents Money market funds $ 58,406 $ — $ — $ 58,406 Marketable securities Corporate bonds — 12,472 — 12,472 U.S. Treasuries — 79,103 — 79,103 Total marketable securities — 91,575 — 91,575 Restricted cash equivalents Money market funds 2,413 — — 2,413 Total $ 60,819 $ 91,575 $ — $ 152,394 December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents Money market funds $ 95,339 $ — $ — $ 95,339 Marketable securities Corporate bonds — 12,609 — 12,609 U.S. Treasuries — 75,059 — 75,059 Total marketable securities — 87,668 — 87,668 Restricted cash equivalents Money market funds 2,413 — — 2,413 Total $ 97,752 $ 87,668 $ — $ 185,420 The fair value of the Company’s cash equivalents and restricted cash equivalents is based on quoted market prices in active markets with no valuation adjustment. The fair value of marketable securities was determined based on observable market inputs. There were no transfers between levels from the year ended December 31, 2021 .

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	5. Property and Equipment, Net Property and equipment, net consisted of the following: March 31, December 31, (in thousands) 2022 2021 Computer equipment and software $ 880 $ 317 Furniture and equipment 482 108 Laboratory equipment 8,896 8,457 Leasehold improvements 55 55 Manufacturing equipment 3,405 — Construction in progress 559 — Total 14,277 8,937 Less: Accumulated depreciation ( 2,510 ) ( 2,084 ) Property and equipment, net $ 11,767 $ 6,853 Depreciation expense for the three months ended March 31, 2022 and 2021 was $ 0.4 million and $ 0.3 million , respectively.

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Accrued Liabilities	6. Accrued Liabilities Accrued liabilities consisted of the following: March 31, December 31, (in thousands) 2022 2021 Employee-related and other expenses $ 2,286 $ 4,178 Research and development expenses 2,946 797 Professional fees 1,993 743 Property and equipment 1,556 — Other 477 617 Total accrued liabilities $ 9,258 $ 6,335

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	. Stock-Based Compensation Stock Incentive Plan As of March 31, 2022, the Company had 2,548,834 shares of its common stock available for future issuance under its stock incentive plan. Stock Options The Company’s stock options generally vest over 48 months with 25 % vesting after one year followed by ratable monthly vesting over the remaining three years and have a contractual term of 10 years. The weighted-average assumptions used principally in determining the fair value of options granted were as follows: Three Months Ended March 31, 2022 2021 Fair value of common stock $ 8.58 $ 22.51 Expected term (in years) 6.0 6.0 Expected volatility 78.3 % 79.7 % Risk-free interest rate 1.7 % 0.7 % Dividend yield — — During the three months ended March 31, 2022 and 2021, the Company granted stock options to purchase 1,818,298 shares and 394,934 shares of its common stock, respectively, with a weighted-average grant-date fair value of $ 5.84 and $ 15.27 per share, respectively. As of March 31, 2022, total unrecognized compensation expense related to stock options was $ 20.9 million, which is expected to be recognized over a weighted-average period of 2.84 years. As of March 31, 2022, options for 165,348 shares of Company common stock with a weighted average exercise price of $ 1.97 were exercised and unvested. The underlying proceeds from the unvested exercises of $ 0.3 million is recorded in other current liabilities on the condensed consolidated balance sheet. Stock-Based Compensation Stock-based compensation expense was allocated as follows: Three Months Ended March 31, (in thousands) 2022 2021 Research and development $ 796 $ 449 General and administrative 950 442 Total stock-based compensation expense $ 1,746 $ 891

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	8. Leases Cambridgepark Lease Amendments On June 15, 2021, the Company entered into the first lease amendment (“First Lease Amendment”) and second lease amendment (“Second Lease Amendment” and, together with the First Lease Amendment, the “Lease Amendments”) with PPF Off 100 Cambridge Park Drive, LLC (the “Landlord”). The Lease Amendments amended the Company’s lease agreement for its corporate office and laboratory facilities with the Landlord in Cambridge, Massachusetts to add additional leased space in the same building (the “Amended Cambridgepark Lease”). The First Lease Amendment commenced for accounting purposes on January 28, 2022 . The term of the First Lease Amendment is through August 2030 with approximately $ 8.4 million in fixed payments. There are no options to extend the First Lease Amendment. The Second Lease Amendment expands the amount of space leased by the Company by an additional 30,175 square feet in exchange for aggregate total fixed rent payments of approximately $ 21.9 million with the annual fixed rental payments escalating from $ 1.2 million to $ 3.0 million during the term. The Second Lease Amendment’s term is expected to commence during the second quarter of 2022 . Payments due associated with the Lease Amendments include fixed and variable payments. Variable payments relate to the Company’s share of the Landlord’s operating costs associated with the underlying assets and are recognized when the event on which those payments are assessed. The Amended Cambridgepark Lease does not contain a residual value guarantee. The Lease Amendments term end dates are coterminous with the existing lease agreement. In conjunction with the Lease Amendments, the Company was required to increase its irrevocable standby letter of credit to $ 2.4 million for the benefit of the Landlord, which has been secured by money market investments and is presented as restricted cash equivalents. For further information regarding the Company’s Cambridgepark lease, please see Note 10 to the condensed consolidated financial statements included in the 2021 Annual Report. The elements of lease expense were as follows: Three Months Ended March 31, (in thousands) 2022 2021 Operating lease cost $ 920 $ 747 Short-term lease cost — 52 Variable lease cost 341 122 Total lease cost $ 1,261 $ 921 Amounts reported in the condensed consolidated balances and the weighted-average lease term and discount rate information were as follows: (in thousands except weighted-average amounts) March 31, 2022 December 31, 2021 Assets Operating right-of-use assets $ 21,597 $ 15,670 Liabilities Operating lease liabilities, current $ 7,281 $ 1,839 Operating lease liabilities, non-current $ 21,677 $ 16,174 Total lease liabilities $ 28,958 $ 18,013 Weighted Average Lease Term and Discount Rate Weighted-average remaining lease term (years) 8.4 8.64 Weighted-average discount rate 8.7 % 9.4 % The following table represents other lease activity: Three Months Ended March 31, (in thousands) 2022 2021 Other Information Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 727 $ 442 Right-of-use assets obtained in exchange for lease obligations $ 6,377 $ —

Significant Agreements

Significant Agreements	3 Months Ended
	Mar. 31, 2022
Significant Agreements [Abstract]
Significant Agreements	. Significant Agreements Since December 31, 2021, there have been no material changes to the key terms of the Company’s license agreements. For further information regarding the Company’s existing license agreements, please see Note 11 to the condensed consolidated financial statements included in the 2021 Annual Report.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	10. Net Loss Per Share The following table sets forth the computation of the Company’s basic and diluted net loss per share for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, (in thousands, except share and per share amounts) 2022 2021 Numerator: Net loss $ ( 22,737 ) $ ( 13,723 ) Cumulative dividends on redeemable convertible preferred stock — ( 1,228 ) Net loss attributable to common stockholders $ ( 22,737 ) $ ( 14,951 ) Denominator: Weighted-average number of common shares outstanding, basic and diluted 37,293,438 22,263,994 Net loss per share attributable to common stockholders, basic and diluted $ ( 0.61 ) $ ( 0.67 ) As of the three months ended March 31, 2022 and 2021, the Company’s potentially dilutive securities were stock options and unvested restricted stock. The Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: As of March 31, 2022 2021 Options to purchase common stock 6,341,581 5,081,678 Unvested restricted stock 165,348 359,719

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the condensed consolidated financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: estimating the fair value of the Company’s common stock (prior to its initial public offering); accrued expenses and research and development expenses.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. The accompanying condensed consolidated balance sheet as of December 31, 2021 has been derived from the Company’s audited consolidated financial statements for the year ended December 31, 2021. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report”). During the three months ended March 31, 2022, other than the adoption of ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , as discussed below, and addition of the cloud computing arrangement accounting policy, there have been no changes to the Company’s significant accounting policies as described in the 2021 Annual Report.
Measurement of Credit Losses	Measurement of Credit Losses For financial assets measured at fair value through other comprehensive loss, the Company must record an allowance for credit losses at the end of each reporting period in the condensed consolidated statement of operations. When developing an estimate of expected credit losses on financial assets, the Company will consider available information relevant to assessing the collectability of cash flows. This information may include internal information, external information, or a combination of both, relating to past events, current conditions, and reasonable and supportable forecasts for financial asset pools. The Company’s investment in corporate bonds and U.S. treasury securities, reported as available-for-sale investments, and the associated accrued interest reported as other current assets on the condensed consolidated balance sheets, is the only financial asset pool. The financial asset pool was determined by the type of financial asset instrument and its credit quality. Management does not expect a credit loss with this financial asset pool and determined an allowance was not required based on the issuers' current high quality credit ratings and the lack of default history on its obligations.
Cloud Computing Arrangements	Cloud Computing Arrangements The Company capitalizes implementation costs for cloud computing arrangement service contracts. The Company’s cloud computing arrangements relate to its enterprise resource planning and manufacturing software. These assets are classified as software and included in property and equipment, net in the consolidated balance sheets and are amortized on a straight-line basis over their assessed useful life beginning when the contract is ready for its intended use. The estimated useful lives of these assets is three years and are subject to the Company’s existing Impairment of Long-Lived Assets accounting policy as described in the 2021 Annual Report.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13 , Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which has been subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10, ASU 2019-11 and ASU 2020-03 (“ASU 2016-13”). This standard requires that credit losses be recorded using an expected losses model rather than the incurred losses model that was previously used and establishes additional credit risk disclosures associated with financial assets. The adoption of this standard on January 1, 2022, did no t have a significant impact on the Company’s financial statements.

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Summary of Amortized Cost and Estimated Fair Value of Marketable Securities by Contractual Maturity	The amortized cost and estimated fair value of marketable securities, by contractual maturity are as follows: March 31, 2022 (in thousands) Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Maturing in one year or less Corporate bonds $ 7,577 $ — $ ( 26 ) $ 7,551 U.S. Treasuries 55,097 — ( 525 ) 54,572 Maturing after one year through five years Corporate bonds 5,005 — ( 84 ) 4,921 U.S. Treasuries 24,968 — ( 437 ) 24,531 Total $ 92,647 $ — $ ( 1,072 ) $ 91,575 December 31, 2021 (in thousands) Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Maturing in one year or less Corporate bonds $ 7,603 $ — $ — $ 7,603 U.S. Treasuries 30,119 — — 30,119 Maturing after one year through five years Corporate bonds 5,006 — — 5,006 U.S. Treasuries 44,940 — — 44,940 Total $ 87,668 $ — $ — $ 87,668 The unrealized losses of the Company’s marketable securities above were a result of market interest rate increases. The contractual terms of those investments do not permit the issuer to settle the securities at a price less than par value. The Company’s intent is to hold the investments until their maturity and any change in fair value that is not credit related is recognized as an other comprehensive income (loss), net of applicable taxes. A credit-related impairment is recognized as an allowance to the balance sheet with a corresponding adjustment to earnings. The Company did no t recognize any credit losses related to marketable securities for the three months ended March 31, 2022.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis: March 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents Money market funds $ 58,406 $ — $ — $ 58,406 Marketable securities Corporate bonds — 12,472 — 12,472 U.S. Treasuries — 79,103 — 79,103 Total marketable securities — 91,575 — 91,575 Restricted cash equivalents Money market funds 2,413 — — 2,413 Total $ 60,819 $ 91,575 $ — $ 152,394 December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents Money market funds $ 95,339 $ — $ — $ 95,339 Marketable securities Corporate bonds — 12,609 — 12,609 U.S. Treasuries — 75,059 — 75,059 Total marketable securities — 87,668 — 87,668 Restricted cash equivalents Money market funds 2,413 — — 2,413 Total $ 97,752 $ 87,668 $ — $ 185,420

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following: March 31, December 31, (in thousands) 2022 2021 Computer equipment and software $ 880 $ 317 Furniture and equipment 482 108 Laboratory equipment 8,896 8,457 Leasehold improvements 55 55 Manufacturing equipment 3,405 — Construction in progress 559 — Total 14,277 8,937 Less: Accumulated depreciation ( 2,510 ) ( 2,084 ) Property and equipment, net $ 11,767 $ 6,853

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following: March 31, December 31, (in thousands) 2022 2021 Employee-related and other expenses $ 2,286 $ 4,178 Research and development expenses 2,946 797 Professional fees 1,993 743 Property and equipment 1,556 — Other 477 617 Total accrued liabilities $ 9,258 $ 6,335

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Summary of Weighted-Average Assumptions Used Principally in Determining Fair Value of Options Granted	The weighted-average assumptions used principally in determining the fair value of options granted were as follows: Three Months Ended March 31, 2022 2021 Fair value of common stock $ 8.58 $ 22.51 Expected term (in years) 6.0 6.0 Expected volatility 78.3 % 79.7 % Risk-free interest rate 1.7 % 0.7 % Dividend yield — —
Summary of Stock-Based Compensation Expense	Stock-based compensation expense was allocated as follows: Three Months Ended March 31, (in thousands) 2022 2021 Research and development $ 796 $ 449 General and administrative 950 442 Total stock-based compensation expense $ 1,746 $ 891

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Summary of Lease Expense	The elements of lease expense were as follows: Three Months Ended March 31, (in thousands) 2022 2021 Operating lease cost $ 920 $ 747 Short-term lease cost — 52 Variable lease cost 341 122 Total lease cost $ 1,261 $ 921
Summary of Amounts Reported in Condensed Consolidated Balances and Weighted-average Lease Term and Discount rate Information	Amounts reported in the condensed consolidated balances and the weighted-average lease term and discount rate information were as follows: (in thousands except weighted-average amounts) March 31, 2022 December 31, 2021 Assets Operating right-of-use assets $ 21,597 $ 15,670 Liabilities Operating lease liabilities, current $ 7,281 $ 1,839 Operating lease liabilities, non-current $ 21,677 $ 16,174 Total lease liabilities $ 28,958 $ 18,013 Weighted Average Lease Term and Discount Rate Weighted-average remaining lease term (years) 8.4 8.64 Weighted-average discount rate 8.7 % 9.4 %
Summary of Other Lease Activity	The following table represents other lease activity: Three Months Ended March 31, (in thousands) 2022 2021 Other Information Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 727 $ 442 Right-of-use assets obtained in exchange for lease obligations $ 6,377 $ —

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of the Company’s basic and diluted net loss per share for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, (in thousands, except share and per share amounts) 2022 2021 Numerator: Net loss $ ( 22,737 ) $ ( 13,723 ) Cumulative dividends on redeemable convertible preferred stock — ( 1,228 ) Net loss attributable to common stockholders $ ( 22,737 ) $ ( 14,951 ) Denominator: Weighted-average number of common shares outstanding, basic and diluted 37,293,438 22,263,994 Net loss per share attributable to common stockholders, basic and diluted $ ( 0.61 ) $ ( 0.67 )
Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share	As of the three months ended March 31, 2022 and 2021, the Company’s potentially dilutive securities were stock options and unvested restricted stock. The Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: As of March 31, 2022 2021 Options to purchase common stock 6,341,581 5,081,678 Unvested restricted stock 165,348 359,719

Nature of the Business - Additi

Nature of the Business - Additional Information (Details)	3 Months Ended
	Mar. 31, 2022
Nature Of Business [Line Items]
Incorporation date	Dec. 30, 2015

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, immaterial effect [true false]	true
Accounting standards update [Extensible list]	us-gaap:AccountingStandardsUpdate201613Member

Marketable Securities - Summary

Marketable Securities - Summary of Amortized Cost and Estimated Fair Value of Marketable Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 92,647	$ 87,668
Gross Unrealized Holding losses	(1,072)
Fair Value	91,575	87,668
Maturing in One Year or Less | Corporate Bonds
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	7,577	7,603
Gross Unrealized Holding losses	(26)
Fair Value	7,551	7,603
Maturing in One Year or Less | U.S. Treasuries
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	55,097	30,119
Gross Unrealized Holding losses	(525)
Fair Value	54,572	30,119
Maturing after One Year through Five Years | Corporate Bonds
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	5,005	5,006
Gross Unrealized Holding losses	(84)
Fair Value	4,921	5,006
Maturing after One Year through Five Years | U.S. Treasuries
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	24,968	44,940
Gross Unrealized Holding losses	(437)
Fair Value	$ 24,531	$ 44,940

Marketable Securities - Additio

Marketable Securities - Additional Information (Details)	3 Months Ended
	Mar. 31, 2022USD ($)
Investments, Debt and Equity Securities [Abstract]
Credit losses related to marketable securities	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	$ 152,394	$ 185,420
Marketable Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	91,575	87,668
Marketable Securities | Corporate Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	12,472	12,609
Marketable Securities | U.S. Treasuries
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	79,103	75,059
Cash Equivalents | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	58,406	95,339
Restricted Cash Equivalents | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	2,413	2,413
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	60,819	97,752
Level 1 | Cash Equivalents | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	58,406	95,339
Level 1 | Restricted Cash Equivalents | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	2,413	2,413
Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	91,575	87,668
Level 2 | Marketable Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	91,575	87,668
Level 2 | Marketable Securities | Corporate Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	12,472	12,609
Level 2 | Marketable Securities | U.S. Treasuries
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	$ 79,103	$ 75,059

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	3 Months Ended
	Mar. 31, 2022USD ($)
Fair Value Disclosures [Abstract]
Fair value assets, level 1 to level 2 transfers amount	$ 0
Fair value assets, level 2 to level 1 transfers amount	0
Fair value assets, transfers into level 3	0
Fair value assets, transfers out of level 3	$ 0

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Total	$ 14,277	$ 8,937
Less: Accumulated depreciation	(2,510)	(2,084)
Property and equipment, net	11,767	6,853
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Total	880	317
Furniture and Equipment
Property Plant And Equipment [Line Items]
Total	482	108
Laboratory Equipment
Property Plant And Equipment [Line Items]
Total	8,896	8,457
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total	55	$ 55
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Total	3,405
Construction in Progress
Property Plant And Equipment [Line Items]
Total	$ 559

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 426	$ 311

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Employee-related and other expenses	$ 2,286	$ 4,178
Research and development expenses	2,946	797
Professional fees	1,993	743
Property and equipment	1,556
Other	477	617
Total accrued expenses	$ 9,258	$ 6,335

Equity - Additional Information

Equity - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)shares
Class Of Stock [Line Items]
Gross proceeds from stock issued | $	$ 45,375
Series B
Class Of Stock [Line Items]
Redeemable convertible preferred stock, issued and sold | shares	87,259,605

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	1,818,298	394,934
Weighted-average grant-date fair value of options granted	$ 5.84	$ 15.27
Unrecognized compensation expense related to stock options	$ 20.9
Unrecognized share based compensation expense, recognition period	2 years 10 months 2 days
Number unvested options	165,348
Weighted average exercise price of options exercised and unvested	$ 1.97
Proceeds from unvested options exercises	$ 0.3
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting rights description	vest over 48 months with 25% vesting after one year followed by ratable monthly vesting over the remaining three years
Vesting period	48 months
Contractual term	10 years
Weighted-average grant-date fair value of options granted	$ 8.58	$ 22.51
Tranche One | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	1 year
Vesting percentage	25.00%
Tranche Two | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	3 years
2021 Plan | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future issuance	2,548,834

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Weighted-Average Assumptions Used Principally in Determining Fair Value of Options Granted (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock	$ 5.84	$ 15.27
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock	$ 8.58	$ 22.51
Expected term (in years)	6 years	6 years
Expected volatility	78.30%	79.70%
Risk-free interest rate	1.70%	0.70%
Dividend yield	0.00%	0.00%

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,746	$ 891
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	796	449
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 950	$ 442

Leases - Additional Information

Leases - Additional Information (Details) $ in Millions	Jun. 15, 2021USD ($)ft²
Standby Letters of Credit
Lessee Lease Description [Line Items]
Increase in irrevocable line of credit facility	$ 2.4
First Lease Amendment
Lessee Lease Description [Line Items]
Operating lease commencement date	Jan. 28, 2022
Lessee, Operating Lease, Existence of Option to Extend [true false]	false
Aggregate total fixed rent payments	$ 8.4
Second Lease Amendment
Lessee Lease Description [Line Items]
Additional space leased | ft²	30,175
Aggregate total fixed rent payments	$ 21.9
Operating lease estimated to commence period	second quarter of 2022
Minimum | Second Lease Amendment
Lessee Lease Description [Line Items]
Increase in annual fixed rental payments	$ 1.2
Maximum | Second Lease Amendment
Lessee Lease Description [Line Items]
Increase in annual fixed rental payments	$ 3

Leases - Summary of Lease Expen

Leases - Summary of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Operating lease cost	$ 920	$ 747
Short-term lease cost		52
Variable lease cost	341	122
Total lease cost	$ 1,261	$ 921

Leases - Summary of Amounts Rep

Leases - Summary of Amounts Reported in Condensed Consolidated Balances and Weighted-average Lease Term and Discount rate Information (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets
Operating right-of-use assets	$ 21,597	$ 15,670
Liabilities
Operating lease liabilities, current	7,281	1,839
Operating lease liabilities, non-current	21,677	16,174
Total lease liabilities	$ 28,958	$ 18,013
Weighted Average Lease Term and Discount Rate
Weighted-average remaining lease term (years)	8 years 4 months 24 days	8 years 7 months 20 days
Weighted-average discount rate	8.70%	9.40%

Leases - Summary of Other Lease

Leases - Summary of Other Lease Activity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$ 727	$ 442
Right-of-use assets obtained in exchange for lease obligations	$ 6,377

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net loss	$ (22,737)	$ (13,723)
Cumulative dividends on redeemable convertible preferred stock		(1,228)
Net loss attributable to common stockholders	$ (22,737)	$ (14,951)
Denominator:
Weighted-average number of common shares outstanding, basic and diluted	37,293,438	22,263,994
Net loss per share attributable to common stockholders, basic and diluted	$ (0.61)	$ (0.67)

Net Loss Per Share - Potential

Net Loss Per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per share	6,341,581	5,081,678
Unvested Restricted Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per share	165,348	359,719